Open access
Aug 2026
Moxifloxacin-Mediated Downregulation of Intestinal P-Glycoprotein Alters the Pharmacokinetics of Dabigatran Etexilate: Mechanistic Insights in Rats and PBPK Model-Informed Dose Optimization
MFLX increases DAB exposure by reducing SBA-regulated intestinal P-gp function by reducing SBA-regulated intestinal P-gp function, and PBPK simulations suggest a low risk of DDI from MFLX coadministration alone; however, caution is warranted in patients with aging or renal impairment.
Yuchen Qu, Zhuan Yang, Wen Ma et al.
· Pharmaceutics · 0 citations